Yintong Huang

Dr. Yintong Huang

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WJWei Jiang
Wei Jiang
XYXubin Yang
Xubin Yang
BLBeisi Lin
Beisi Lin
ZLZhigu Liu
Zhigu Liu
XCXuanrong Chen
Xuanrong Chen
LZLongyi Zeng
Longyi Zeng
Objective: To evaluate the impact of intensive insulin therapy (IIT) within 1 week on glycemic control and β-cell function indices in patients with type 2 diabetes mellitus (T2DM). Methods: This retrospective study included 726 patients with T2DM who underwent continuous subcutaneous insulin infusion within 1 week. Patients were divided into three groups based on disease duration: short (≤1 year), medium (>1 and <10 years), and long (≥10 years) duration groups. The primary outcome was the changes in glycemic control and β-cell function indices after IIT. Factors influencing the improvement in β-cell function metrics were also analyzed. Results: After IIT within 1 week, fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels significantly decreased (p < 0.01 for both). HOMA-β, 30 min insulinogenic index, 30 min disposition index, and insulin secretion sensitivity index-2 markedly improved from baseline [37.69 (41.03) VS. 32.40 (46.06), 3.16 (3.97) VS. 2.12 (3.51), 336.85 (397.05) VS. 188.93 (263.45), and 185.92 (122.89) VS. 120.81 (90.12), respectively] (p < 0.01 for all). Insulin sensitivity, measured by HOMA-IR and Matsuda index, significantly improved (p < 0.01 for both). Significantly greater improvements in glycemic control and β-cell function measures were observed in patients with a shorter diabetes duration. Age, duration of diabetes, BMI, HbA1c, duration of IIT, and time in range were significantly associated with improvements in β-cell function indices. Conclusions: IIT within 1 week was associated with improved glycemic control and β-cell function indices in T2DM patients, with the most pronounced benefits observed in those with a shorter disease duration.